Therapeutics
-
CRISPR-CasΦ from huge phages is a hypercompact genome editor
Pausch P, Al-Shayeb B, Bisom-Rapp E, et al. Science. 2020 Jul 17; 369(6501): 333–337. doi: 10.1126/science.abb1400Learn More -
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases.
Jones SK, Hawkins JA, Johnson NV, Jung C, Hu K, Rybarski JR, Chen JS, Doudna JA, Press WH, Finkelstein IJ. https://www.biorxiv.org/content/10.1101/696393v1.Learn More -
Deciphering Off-Target Effects in CRISPR-Cas9 through Accelerated Molecular Dynamics.
Ricci CG, Chen JS, Miao Y, et al. ACS Cent Sci. 2019;5(4):651–662. doi:10.1021/acscentsci.9b00020Learn More -
Programmed DNA destruction by miniature CRISPR-Cas14 enzymes.
Harrington LB, Burstein D, Chen JS, et al. Science. 2018;362(6416):839–842. doi:10.1126/science.aav4294Learn More -
A thermostable Cas9 with increased lifetime in human plasma.
Harrington LB, Paez-Espino D, Staahl BT, et al. Nat Commun. 2017;8(1):1424. Published 2017 Nov 10. doi:10.1038/s41467-017-01408-4Learn More -
Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
Chen JS, Dagdas YS, Kleinstiver BP, et al. Nature. 2017;550(7676):407–410. doi:10.1038/nature24268Learn More -
A Broad-Spectrum Inhibitor of CRISPR-Cas9.
Harrington LB, Doxzen KW, Ma E, et al. Cell. 2017;170(6):1224–1233.e15. doi:10.1016/j.cell.2017.07.037Learn More -
Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering.
Nuñez JK, Harrington LB, Doudna JA. ACS Chem Biol. 2016;11(3):681–688. doi:10.1021/acschembio.5b01019Learn More -